Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 11/20 | 0.50 |
| ▸ | CA12 | O43570 | 10/20 | 0.50 |
| ▸ | CA1 | P00915 | 10/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 6/20 | 0.45 |
| ▸ | CA5A | P35218 | 6/20 | 0.45 |
| ▸ | CA7 | P43166 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019176 | 0.99 | THRB (0.53) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL10056659 | 0.99 | THRB (0.53) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL15906267 | 0.91 | CYP2D6 (0.57) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL3794899 | 0.89 | CYP2D6 (0.56) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL9614375 | 0.89 | CYP2D6 (0.56) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL9614389 | 0.89 | CYP2D6 (0.56) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL3794903 | 0.89 | CYP2D6 (0.56) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL16946235 | 0.89 | CYP2D6 (0.56) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL14342159 | 0.89 | CYP2D6 (0.56) | CYP2D6THRBHSD17B10TSHRNR3C1 | |
| SCHEMBL13713745 | 0.89 | CYP2D6 (0.56) | CYP2D6THRBHSD17B10TSHRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604505-A1 | NOVEL MONOOXYGENASE AND UTILIZATION THEREOF | Kaneka Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-8106023-B2 | 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-8106023-B2 | 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20100035834-A1 | NOVEL 1,4-BENZOTHIEPIN-1, 1-DIOXIDE DERIVATIVES WITH IMPROVED PROPERTIES METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS DEUTUSCHLAND GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035834-A1 | NOVEL 1,4-BENZOTHIEPIN-1, 1-DIOXIDE DERIVATIVES WITH IMPROVED PROPERTIES METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS DEUTUSCHLAND GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| WO-2008058631-A1 | NOVEL 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES WITH IMPROVED PROPERTIES, METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-22 | — | — | WO | disclosed |
| US-5656721-A | HAVING SUGAR MOIETY; PROLONGED DURATION OF ACTION | SANDOZ LTD. (CH) | 1997-08-12 | — | — | US | disclosed |
| EP-0472220-A1 | Bradykinin antagonists | SYNTEX (U.S.A.) INC. (US) | 1992-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035834-A1 | NOVEL 1,4-BENZOTHIEPIN-1, 1-DIOXIDE DERIVATIVES WITH IMPROVED PROPERTIES METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | PTGS1, TBXAS1, SULT1E1 | CYP2D6 49/4885THRB 4607/4885HSD17B10 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.